RecruitingHereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Eligible age

18+ yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

Sponsor: ADARx Pharmaceuticals, Inc.

You may qualify if…

✓ Have a documented diagnosis of HAE (Type I or II)
✓ Completed Study ADX-324-301
✓ Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)